The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Abstract
Glecirasib (JAB-21822) is a new covalent oral KRAS-G12C inhibitor. This multicenter, single-arm phase 2b study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRAS G12C-mutated nonsmall-cell lung cancer. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC). Between 15 September 2022 and 28 September 2023, 119 patients with a median age of 62 years were enrolled. As of the data cut-off date on 28 March 2024, the ORR assessed by IRC was 47.9% (56/117; 95% confidence interval: 38.5-57.3%). The incidence of treatment-related adverse events (TRAEs) of any grade was 97.5% (116/119). The incidence of grades 3 and 4 TRAEs was 38.7% (46/119). A total of 5.0% (6/119) of patients discontinued the treatment due to TRAEs. No treatment-related deaths occurred. Glecirasib exhibited promising clinical efficacy and manageable safety profiles in these patient populations. ClinicalTrials.gov identifier: NCT05009329 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849 · cited 4×
“In the phase 2 study of sotorasib, the ORR and DCR assessed by IRC were 37.1% and 80.6%, respectively 15 .”
InfluentialGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309 · cited 1×
“…size of approximately 111 patients would provide more than 90% power to demonstrate that the lower boundary of the two-sided 95% CI would exceed the null hypothesis of 23%, as the ORR observed in the REVEL trial 16 with the alternative hypothesis of 37% determined on the efficacy assumption 15 .”
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061 · cited 3×
“The incidences of any grade diarrhea, nausea and vomiting were 31.7–33.7%, 14.2–19.0% and 4.7–7.9%, respectively, in the sotorasib study 17 , and 70.7%, 69.8% and 56.9%, respectively, in the adagrasib study 18 .”
InfluentialSelf-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619 · cited 2×
“The incidences of any grade diarrhea, nausea and vomiting were 31.7–33.7%, 14.2–19.0% and 4.7–7.9%, respectively, in the sotorasib study 17 , and 70.7%, 69.8% and 56.9%, respectively, in the adagrasib study 18 .”
InfluentialSelf-citationConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07205-6 · Cited by 369 · cited 1×
“New KRAS or pan-RAS inhibitors have exhibited anticancer efficacy in pre-clinical studies that can target other types of KRAS alterations and even wild-type of RAS 25,26 .”
Self-citation
Cited by
Emerging landscape of KRAS inhibitors in cancer treatment
Riedl, J. M., Matsubara, H., McNeil, R., Patel, P. S., de la Cruz, F. F., Gulhan, D., & Corcoran, R. B. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.001 · Cited by 53
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
Cho, B. C., Lü, S., Lee, M. A., Song, Z., Park, J., Lim, S. M., Li, Z., Zhao, J., Richardson, G. E., Zhang, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03688-6 · Cited by 28
Self-citationRuan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02274-z · Cited by 22
Self-citationEvolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 29
Li, J., Deng, T., Gu, Y., Calles, A., Li, Z., Bai, C., Wu, L., Huang, J., Li, X., Yao, Y., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.70056 · Cited by 21
Self-citation
Metadata
- Authors
- Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., Yang, R., Wang, Z., Zhao, E., Wang, M., Zhao, Y., Tang, K., Li, Z., Song, Z., Li, Y., Zhuang, W., Jin, B., Cheng, Y., Hu, Y., Gu, Y., Wu, L., Ma, R., Yu, Q., Yu, Y., Zhao, J., Zhao, H., Lv, D., Shang, Y., Xing, P., Zhou, J., Li, X., Liu, Z., Dai, Z., Xia, G., Chen, X., Ba, Y., Bai, C., Li, Q., An, G., Hu, W., Wang, Y., Wang-Gillam, A., Ding, Y., Li, Q., & Rao, Z.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University Cancer Hospital (CN)
- Shandong Tumor Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Qilu Hospital of Shandong University (CN)
- West China Hospital of Sichuan University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Capital Medical University (CN)
- Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province (CN)
- Peking Union Medical College Hospital (CN)
- Henan Cancer Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Zhejiang Cancer Hospital (CN)
- Chongqing Cancer Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- First Hospital of China Medical University (CN)
- Jilin Province Tumor Hospital (CN)
- Hubei Cancer Hospital (CN)
- Jiangsu Province Hospital (CN)
- Hunan Cancer Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Guangxi Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Affiliated Hospital of Hebei University (CN)
- Sichuan Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Dalian Medical University (CN)
- Jiangsu Cancer Hospital (CN)
- Hangzhou Cancer Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Chengde Medical University (CN)
- Renmin Hospital of Wuhan University (CN)
- Corresponding author
- Shi, Yuankai
- ORCID
- Shi, Yuankai
- Fang, Jian
- Xing, Ligang
- Yao, Yu
- Zhang, Jian
- Liu, Lian
- Wang, Yongsheng
- Xiong, Jianping
- Liu, Zhihua
- Yang, Runxiang
- Zhao, Enfeng
- Wang, Mengzhao
- Zhao, Yanqiu
- Tang, Kejing
- Song, Zhengbo
- Li, Yongsheng
- Zhuang, Wu
- Jin, Bo
- Cheng, Ying
- Hu, Yanping
- Gu, Yanhong
- Wu, Lin
- Ma, Rui
- Yu, Qitao
- Yu, Yan
- Zhao, Jun
- Zhao, Hui
- Lv, Dongqing
- Xing, Puyuan
- Zhou, Jin
- Li, Xingya
- Liu, Zhe
- Dai, Zhaoxia
- Ba, Yi
- Bai, Chunmei
- Li, Qingshan
- Hu, Weiguo
- Wang, Yinxiang
- Ding, Yuli
- Li, Qiao
- Venue
- Nature Medicine
- Published
- 2025-01-06
- Volume
- 31
- Issue
- 3
- Pages
- 894-900
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4406104531
- Cited by
- 42
- References
- 32
- Citations by year
- 2026: 23 · 2025: 19
- FWCI
- 27.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Academy of Medical Sciences
- Chinese Academy of Sciences
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- KRAS G12C mutation, non-small cell lung cancer, KRAS G12C inhibitors, covalent inhibitors, oral targeted therapy, objective response rate, treatment-related adverse events, metastatic lung cancer, locally advanced lung cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. https://app.cochat.ai/papers/10.1038/s41591-024-03401-z
- The paper
- Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., Yang, R., Wang, Z., Zhao, E., Wang, M., Zhao, Y., Tang, K., Li, Z., Song, Z., Li, Y., . . . Rao, Z. (2025). Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03401-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.